MyPeptideHelper

Goal

Immune support

Compounds8
With human trials3

Direction matters more than strength here — pushing an overactive system is not a neutral act.

Immune support is a vague request, and the compounds on this page do not grant it. What they do is modulate, which can mean lifting a blunted response or damping an overactive one. That direction is the whole question. If you have an autoimmune condition, an immune-modulating compound is not a wellness decision, and this page is not the place to make it.

Thymosin alpha-1 and LL-37 sit at 5 with very different footing. Thymosin alpha-1 has genuine clinical standing: marketed as thymalfasin, approved in a number of countries outside the US for chronic hepatitis B and C and as a vaccine adjuvant, with a labeled 1.6 mg twice-weekly regimen that is the only dosing on this page anchored to an approval. LL-37 is the human cathelicidin, a real host-defense peptide, but its evidence base is overwhelmingly in vitro and animal, and there is no established systemic dosing regimen at all. KPV at 4 and ARA-290 at 3 act on the anti-inflammatory side; epitalon, larazotide and Selank appear at 2 through more indirect routes.

Separate an acute use — a short course around a recurring infection pattern — from chronic modulation, which is a much bigger claim and much thinner ground. Note also that the evidence tier shown against each compound describes that compound as a whole rather than its immune use specifically; the monograph is where the indication-by-indication detail lives.

How to read this

Match — how squarely it aims here

The weight the dataset gives this compound for this goal, 1 to 5. It describes intent and mechanism, not benefit, and not direction: a 5 means the compound acts hard on the system in question.

5/5Match strength 5 of 5primary use

Evidence — whether anyone has shown it

Read from the compound’s evidence note and handling grade, for the compound as a whole rather than for this goal alone. A 5/5 match on animal data is a hypothesis, not a result.

  • Human trialsRandomized or controlled human trials exist, or the compound holds a regulatory approval somewhere. Trials existing is not the same as trials succeeding — some of these were negative.
  • Some human dataPublished human work exists but is small, early-phase, acute, or from a single group that nobody has replicated.
  • Animal data onlyThe case rests on rodent and cell work. Doses shown are extrapolated, not established in people.
  • Anecdotal onlyNo published trial record of any kind. Every number comes from vendor packaging and community practice.

8 compounds, strongest match first

Ranked for immune support

Match 5/5 · Primary use

2

Match 4/5 · Strong secondary

1

Match 3/5 · Meaningful contributor

2

Match 2/5 · Marginal

3

Named stacks

Protocols built around this goal

Energy / Immunity (NAD+ + Glutathione + Methyl-B12)Also targets8 weeksBeginnerThe three things that end up in almost every "energy and immunity" product: NAD+ for mitochondrial redox, glutathione as the headline antioxidant, and methylcobalamin because B12 is what people associate with energy. They are combined because they are convenient to sell together, not because anyone has shown the three work better in combination than separately.

Not sure this is your goal

Most people arrive wanting two or three of these at once, and the honest answer is usually to pick one and run it properly. The quiz weighs your goals against your experience, the routes you will tolerate and your contraindications, then shows its reasoning rather than just a name.

Take the quiz

Other goals

Educational information only, not medical advice. Talk to a licensed clinician before starting, changing, or stopping anything.